{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Hypertension%2C+Primary%2C+2&page=2", "query": { "condition": "Pulmonary Hypertension, Primary, 2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pulmonary+Hypertension%2C+Primary%2C+2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T18:28:27.614Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02234141", "title": "Selonsertib in Adults With Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Selonsertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 151, "start_date": "2014-11", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2019-04-10", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 24, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234141" }, { "nct_id": "NCT04691154", "title": "A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Arterial Hypertension", "Pulmonary Hypertension Due to Lung Diseases" ], "interventions": [ { "name": "L606 inhalation suspension", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Liquidia Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2021-08-01", "completion_date": "2031-03-31", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04691154" }, { "nct_id": "NCT01265888", "title": "Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension", "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Inhaled Nitric Oxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geno LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 31, "start_date": "2011-03", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-09-19", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265888" }, { "nct_id": "NCT05975905", "title": "A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Dose A KER-012", "type": "BIOLOGICAL" }, { "name": "Dose B KER-012", "type": "BIOLOGICAL" }, { "name": "Dose C KER-012", "type": "BIOLOGICAL" }, { "name": "Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Keros Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2023-10-17", "completion_date": "2025-03-11", "has_results": false, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Stanford, California + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05975905" }, { "nct_id": "NCT02682511", "title": "Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Scleroderma, Diffuse", "Scleroderma, Systemic", "Scleroderma, Limited", "Sclerosis, Progressive Systemic", "Skin Diseases", "Connective Tissue Diseases", "Pathologic Processes", "Autoimmune Diseases" ], "interventions": [ { "name": "Oral Ifetroban", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 34, "start_date": "2017-01", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 10, "location_summary": "Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02682511" }, { "nct_id": "NCT03556020", "title": "Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Pemziviptadil (PB1046)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PhaseBio Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 35, "start_date": "2018-07-15", "completion_date": "2022-01-07", "has_results": false, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 26, "location_summary": "Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03556020" }, { "nct_id": "NCT07073820", "title": "A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "PF-07868489", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2025-11-10", "completion_date": "2028-07-18", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 13, "location_summary": "Sacramento, California • San Francisco, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT07073820" }, { "nct_id": "NCT02664558", "title": "A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "ubenimex", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 61, "start_date": "2016-04", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02664558" }, { "nct_id": "NCT03496207", "title": "A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sotatercept", "type": "DRUG" }, { "name": "SOC", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2018-06-13", "completion_date": "2022-03-09", "has_results": true, "last_update_posted_date": "2023-04-19", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03496207" }, { "nct_id": "NCT04712669", "title": "A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "rodatristat ethyl 300 mg tablet BID", "type": "DRUG" }, { "name": "rodatristat ethyl 600 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Altavant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2021-03-15", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-06-10T18:28:27.614Z", "location_count": 28, "location_summary": "Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04712669" } ] }